US FDA Approved OLPRUVA to Treat Urea Cycle Disorder Patients
Acer Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for the oral suspension of OLPRUVA (sodium phenylbutyrate) to treat certain UCD patients. Chris Schelling, CEO and founder of Acer Therapeutics Inc., said that the approval of OLPRUVA by the US FDA of OLPRUVA marks the culmination of our ongoing […]
Continue Reading